Compass Therapeutics Inc (CMPX) Peer Comparison

$0.75

$0.00 (0.03%)

As on 27-Oct-2026 16:28EDT

Market cap

$137 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

6.4

Div. Yield

0 %

Edit

	Compass Therapeutics Inc (CMPX)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	137	18,719	15,989	16,015	14,259
Revenue ($ Mln)	--	2,838	2,436	1,054	1,664
Net Profit ($ Mln)	-73.45	517.83	860.62	755.85	413.60
Net Margin (%)	--	18.24	35.33	71.69	24.86
RoE (%)	-40.48	87.53	42.98	--	430.03
Price to Earnings	--	37.16	20.36	18.65	36.73
Price-To-Book	6.39	39.67	7.82	9.82	25.20

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Compass Therapeutics Inc (CMPX)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Operating Revenue	0.00	2,838.39	2,435.92	1,054.37	1,663.74
Cost of Revenue	0.74	2,011.22	85.67	103.47	292.42
Gross Profit	-1.47	760.62	2,236.43	588.53	1,167.84
Operating Expenses	80.35	220.03	1,378.74	841.45	440.53
Operating Profit (EBIT)	-81.09	607.14	971.51	109.45	930.79
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-73.45	626.99	1,035.47	101.11	583.34
Provision for Tax	0.00	109.17	174.84	-654.74	169.74
Profit after Tax (Net Income)	-73.45	517.83	860.62	755.85	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Compass Therapeutics Inc (CMPX)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Shareholder's Funds	166.05	584.94	1,843.76	1,435.90	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	8.00	221.56	288.55	384.48	2,089.43
Current Liabilities	16.13	1,496.10	361.93	464.70	344.44
Total Liabilities	219.59	1,975.47	2,844.42	1,302.02	2,525.32

Assets ($ Mln)

	Compass Therapeutics Inc (CMPX)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Non-Current Assets	9.28	1,057.60	1,243.41	895.24	1,644.38
Current Assets	180.89	1,245.00	1,250.82	1,389.84	933.02
Total Assets	219.59	1,975.47	2,844.42	1,302.02	2,525.32
Total Debt*	9.63	146.04	165.93	449.89	2,146.65
Net Current Assets	164.76	0.00	888.90	925.52	588.59

Cashflow ($ Mln)

	Compass Therapeutics Inc (CMPX)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-49.14	713.22	884.27	51.77	651.56
Cash Flow from Investing Activities	-93.31	-31.14	350.44	-8.15	-545.81
Cash from Financing Activities	129.61	-860.39	-969.59	34.89	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Compass Therapeutics Inc (CMPX)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
ROCE (%)	-39.29	57.43	32.82	-30.01	15.61
ROE (%)	-40.48	87.53	42.98	163.18	430.03
ROA (%)	-43.61	15.73	29.32	31.68	16.19
EBIT Margin (%)	--	21.70	41.82	5.73	36.28
Net Margin (%)	--	18.24	35.33	71.69	24.86
Cash Profit Margin (%)	--	0.00	0.00	0.00	0.00

Growth Ratios

	Compass Therapeutics Inc (CMPX)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Revenue Growth (%)	-1.00	20.35	9.23	114.85	41.15
EBIT Growth (%)	-18.41	18.61	29.37	136.39	-14.99
Net Profit Growth (%)	-18.41	19.59	42.89	378.76	-25.78
EPS Growth (%)	6.49	28.06	50.42	353.27	-23.48
Book Value Growth (%)	31.88	108.60	-0.70	816.12	-55.81

Valuation Ratios

	Compass Therapeutics Inc (CMPX)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Price / Earnings	-14.93	36.06	15.79	-59.76	24.99
Price / Book Value	5.04	35.44	5.72	-80.42	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-12.21	27.88	12.44	-121.54	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Compass Therapeutics Inc (CMPX)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Debt to Equity	0.00	0.00	0.00	0.27	13.50
Short term debt to equity ratio	0.01	0.00	0.00	0.05	1.46
Current Ratio	11.22	0.83	3.46	2.99	2.71
Quick Ratio	11.22	0.83	3.38	2.32	2.31
Interest Coverage	--	--	--	1.62	29.73

Operating Efficiency Ratios

	Compass Therapeutics Inc (CMPX)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Debtors to sales (%)	--	15.77	13.74	21.25	27.40
Asset Turnover	0.00	0.86	0.83	0.44	0.65
Receivable days	--	50.42	43.48	85.52	98.04
Inventory Days	--	--	96.17	1,056.70	254.12
Payable days	475.67	6.26	147.97	331.01	24.86
Cash Conversion Cycle	--	--	-8.32	811.21	327.29

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly